Immune dysregulation in cancer patients developing immune-related adverse events

BACKGROUND: Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown. METHODS: Sera from 65 patients receiving im...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Shaheen, Khan, Saad A., Luo, Xin, Fattah, Farjana J., Saltarski, Jessica, Gloria-McCutchen, Yvonne, Lu, Rong, Xie, Yang, Li, Quan, Wakeland, Edward, Gerber, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325132/
https://www.ncbi.nlm.nih.gov/pubmed/30377338
http://dx.doi.org/10.1038/s41416-018-0155-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325132/
https://www.ncbi.nlm.nih.gov/pubmed/30377338
http://dx.doi.org/10.1038/s41416-018-0155-1

Ejemplares similares